Comparison of ampicillin/sulbactam and minocycline combination with ampicillin/sulbactam and colistin combination in the treatment of ventilator-dependent upper respiratory tract (VAP) induced by Acinetobacter: a randomized controlled clinical trial

Evaluating the effectiveness of the combination of ampicillin/sulbactam and minocycline compared to the combination of ampicillin/sulbactam and colistin in the treatment of ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii: a randomized controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150721023282N31

Enrollment

Registered

2026-02-11

Start date

2026-04-04

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator-induced pneumonia. J95.851

Interventions

Intervention 1: Intervention group: Ampicillin/Sulbactam 9 g (6g ampicillin + 3g sulbactam) intravenously via 1-hour infusion every 8 hours, plus Minocycline 200 mg orally every 12 hours, for 10 days.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Under mechanical ventilation (intubation) for more than 48 hours VAP diagnosis Growth of carbapenem (meropenem)-resistant Acinetobacter baumannii in the lung secretions culture

Exclusion criteria

Exclusion criteria: Pregnancy Lactation History of sensitivity to the antibiotics ampicillin/sulbactam, minocycline, or colistin Acute Respiratory Distress Syndrome Having a non-VAP pulmonary lung infection (tuberculosis, COVID-19, aspergillosis, ...)

Design outcomes

Primary

Measure	Time frame
Clinical Response (defined as cure or improvement or treatment failure). Timepoint: End of intervention. Method of measurement: Clinical judgment by the observation of the patient.	—

Secondary

Measure	Time frame
Sequential Organ Failure Assessment (SOFA) Score. Timepoint: Before and after the intervention. Method of measurement: Questionnaire.;Mortality rate during the intervention. Timepoint: The end of intervention. Method of measurement: Counting.;Serum procalcitonin level. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Acute Kidney Injury. Timepoint: During the intervention. Method of measurement: Creatinine.;Liver Injury. Timepoint: During the intervention. Method of measurement: Alanine transaminase(ALT),Aspartate aminotransferase(AST).	—

Measure

Time frame

Sequential Organ Failure Assessment (SOFA) Score. Timepoint: Before and after the intervention. Method of measurement: Questionnaire.;Mortality rate during the intervention. Timepoint: The end of intervention. Method of measurement: Counting.;Serum procalcitonin level. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Acute Kidney Injury. Timepoint: During the intervention. Method of measurement: Creatinine.;Liver Injury. Timepoint: During the intervention. Method of measurement: Alanine transaminase(ALT),Aspartate aminotransferase(AST).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDR. Rasool Soltani

Esfahan University of Medical Sciences

soltani@pharm.mui.ac.ir+98 31 3792 7067

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026